Noble Metal Nanomaterials for NIR-Triggered Photothermal Therapy in Cancer.
Zhuoqian LvSijia HeYoufu WangXinyuan ZhuPublished in: Advanced healthcare materials (2021)
It is of great significance to develop anticancer therapeutic agents or technologies with high degree of specificity and patient compliance, while low toxicity. The emerging photothermal therapy (PTT) has become a new and powerful therapeutic technology due to its noninvasiveness, high specificity, low side effects to normal tissues and strong anticancer efficacy. Noble metal nanomaterials possess strong surface plasmon resonance (SPR) effect and synthetic tunability, which make them facile and effective PTT agents with superior optical and photothermal characteristics, such as high absorption cross-section, incomparable optical-thermal conversion efficiency in the near infrared (NIR) region, as well as the potential of bioimaging. By incorporating with various functional reagents such as antibodies, peptides, biocompatible polymers, chemo-drug and immune factors, noble metal nanomaterials have presented strong potential in multifunctional cancer therapy. Herein, the recent development regarding the application of noble metal nanomaterials for NIR-triggered PTT in cancer treatment is summarized. A variety of studies with good therapeutic effects against cancer from impressive photothermal efficacy of noble metal nanomaterials are concluded. Intelligent nanoplatforms through ingenious fabrication showing potential of multifunctional PTT, combined with chemo-therapy, immunotherapy, photodynamic therapy (PDT), as well as simultaneous imaging modality are also demonstrated.
Keyphrases
- photodynamic therapy
- cancer therapy
- fluorescence imaging
- drug delivery
- high resolution
- drug release
- papillary thyroid
- gene expression
- squamous cell
- quantum dots
- oxidative stress
- stem cells
- ionic liquid
- high speed
- emergency department
- radiation therapy
- human health
- squamous cell carcinoma
- adverse drug
- locally advanced
- fluorescent probe
- risk assessment
- structural basis
- replacement therapy